Cite
HARVARD Citation
Jones, J. et al. (n.d.). P037 Nonclinical pharmacokinetics and absorption, distribution, metabolism, and excretion properties of MORF-057 support its clinical development as an oral selective α4β7 integrin inhibitor. Journal of Crohn's and colitis. pp. S149-S150. [Online].